BYSI
$1.80+0.06 (+3.74%)
Market OpenAs of Mar 17, 6:06 PM UTC
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.80
Potential Upside
5%
Whystock Fair Value$1.90
Price
UndervaluedFair ValueOvervalued
Fundamentals
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodul...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$74.23M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.98
Recent News
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...